DrugPatentWatch Database Preview

King Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for KING PHARMS, and when can generic versions of KING PHARMS drugs launch?

KING PHARMS has twenty-seven approved drugs.

There are six US patents protecting KING PHARMS drugs.

There are seventy-three patent family members on KING PHARMS drugs in thirty-two countries and eight supplementary protection certificates in six countries.

Summary for King Pharms

International Patents:	73
US Patents:	6
Tradenames:	25
Ingredients:	23
NDAs:	27

Drugs and US Patents for King Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
King Pharms	LEVOXYL	levothyroxine sodium	TABLET;ORAL	021301-011	May 25, 2001	AB1,AB3	RX	Yes	Yes	6,555,581
King Pharms Llc	INTAL	cromolyn sodium	SOLUTION;INHALATION	018596-001	May 28, 1982		DISCN	Yes	No
King Pharms	LEVOXYL	levothyroxine sodium	TABLET;ORAL	021301-005	May 25, 2001	AB1,AB3	RX	Yes	No	7,101,569
King Pharms	LEVOXYL	levothyroxine sodium	TABLET;ORAL	021301-003	May 25, 2001	AB1,AB3	RX	Yes	No	7,067,148		Y

Expired US Patents for King Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
King Pharms Llc	ALTACE	ramipril	CAPSULE;ORAL	019901-004	Jan 28, 1991	4,587,258
King Pharms Llc	ALTACE	ramipril	CAPSULE;ORAL	019901-003	Jan 28, 1991	5,403,856
King Pharms Llc	AVINZA	morphine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	021260-001	Mar 20, 2002	6,066,339
King Pharms Llc	TILADE	nedocromil sodium	AEROSOL, METERED;INHALATION	019660-001	Dec 30, 1992	4,474,787

Paragraph IV (Patent) Challenges for KING PHARMS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	800 mg		2004-11-04
	Extended-release Capsules	45 mg and 75 mg		2009-07-30
	Extended-release Capsules	30 mg, 60 mg, 90 mg and 120 mg		2007-06-04

International Patents for King Pharms Drugs

Country	Patent Number	Estimated Expiration
Canada	2626027
World Intellectual Property Organization (WIPO)	0115674
Czech Republic	20020770
World Intellectual Property Organization (WIPO)	03028624

Supplementary Protection Certificates for King Pharms Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1539166	2013/055	Ireland		PRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. QUINIDINE SULPHATE AND IN PARTICULAR QUINIDINE SULPHATE DIHYDRATE, PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/833 20130624
0265685	SPC/GB98/047	United Kingdom		PRODUCT NAME: COMBINATIONS OF RAMIPRIL, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, AND FELODIPINE, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: SE 13596 19970919; SE 13597 19970919; UK 00017/0402 19980825; UK 00017/0403 19980825
0265685	C980030	Netherlands		PRODUCT NAME: FELODIPINE, DESGEWENST IN DE VORM VAN FYSIOLOGISCH AANVAARDBAAR ZOUT, EN (2S, 3AS, 6AS)-1-[(S)-N-[(S)-1-CARBOXY-3-FENYLPROPYL]A LANYL]OCTAHYDROCYCLOPENTA[B]-PYRROOL-2-CARBONZUUR (RAMIPRILAAT) , DESGEWENST IN DE VORM VAN EEN .....ZIE VERDER IN HET DOSSIER; NAT. REGISTRATION NO/ DATE: RVG 22449, RVG 22450 19980618; FIRST REGISTRATION: SE 13596, 13597 19970919
0350733	SPC/GB03/034	United Kingdom		PRODUCT NAME: MOXIFLOXACIN AND PHARMACEUTICALLY USABLE HYDRATES AND ACID ADDITION SALTS THEREOF AND THE ALKALI METAL, ALKALINE EARTH METAL, SILVER AND GUANIDINIUM SALTS OF THE UNDERLYING CARBOXYLIC ACIDS AND THE RACEMATES THEREOF; REGISTERED: DE 45263.00.00 19990621; UK PL 000 10/0291 20030313

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• King Pfizer
• King Pharms
• King Pharms Llc